Context Therapeutics Inc.
CNTXHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeContext Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company carries a $33.2M market cap, placing it firmly in the micro-cap category. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Market Cap
$33.2M
Beta
1.69
P/E (TTM)
—
P/E (Fwd)
-0.83
EPS (TTM)
$-0.48
EPS (Fwd)
$-0.44
ROE
-76.1%
ROA
-45.7%
Cash
$43.0M
Total Debt
$244,992
Free CF
-$31.5M
52W Change
-57.2%
Annual Financials
Cash vs Debt
Where CNTX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CNTX finished 79.43% below its 150-day moving average ($1.75) and 78.18% below its 200-day moving average ($1.65). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CNTX overbought or oversold?
At the September 3, 2026 close, CNTX's RSI(14) was 23.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Context Therapeutics Inc. holds $43.0M in cash against $245K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$31.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -76.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.69 means CNTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Context Therapeutics Inc.'s trajectory.